Pfenex Inc. (PFNX) Cut to Hold at Zacks Investment Research
Zacks Investment Research cut shares of Pfenex Inc. (NYSEAMERICAN:PFNX) from a buy rating to a hold rating in a report issued on Wednesday.
According to Zacks, “Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company’s lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf?nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California. “
Other equities research analysts have also issued research reports about the stock. ValuEngine lowered shares of Pfenex from a hold rating to a sell rating in a research note on Tuesday, August 1st. William Blair reissued an outperform rating on shares of Pfenex in a research note on Thursday, August 10th. Finally, JMP Securities dropped their price objective on shares of Pfenex from $21.00 to $8.00 and set an outperform rating on the stock in a research note on Friday, November 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and one has given a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $5.50.
Pfenex (NYSEAMERICAN:PFNX) opened at $2.81 on Wednesday. Pfenex has a 52-week low of $2.54 and a 52-week high of $10.25.
Pfenex (NYSEAMERICAN:PFNX) last announced its quarterly earnings results on Thursday, November 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.17. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. The company had revenue of $5.02 million for the quarter, compared to analysts’ expectations of $3.30 million. During the same quarter in the previous year, the company earned $1.46 earnings per share. Pfenex’s quarterly revenue was down 89.7% on a year-over-year basis.
COPYRIGHT VIOLATION NOTICE: “Pfenex Inc. (PFNX) Cut to Hold at Zacks Investment Research” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/pfenex-inc-pfnx-cut-to-hold-at-zacks-investment-research/1711399.html.
Hedge funds and other institutional investors have recently modified their holdings of the company. Blair William & Co. IL lifted its stake in shares of Pfenex by 14.2% in the second quarter. Blair William & Co. IL now owns 250,817 shares of the biotechnology company’s stock worth $1,006,000 after buying an additional 31,108 shares in the last quarter. Sanders Morris Harris LLC lifted its stake in shares of Pfenex by 33.9% in the third quarter. Sanders Morris Harris LLC now owns 998,151 shares of the biotechnology company’s stock worth $3,015,000 after buying an additional 252,464 shares in the last quarter. AJO LP bought a new position in shares of Pfenex in the second quarter worth approximately $946,000. Susquehanna International Group LLP bought a new position in shares of Pfenex in the second quarter worth approximately $272,000. Finally, Legal & General Group Plc lifted its stake in shares of Pfenex by 2,567.5% in the second quarter. Legal & General Group Plc now owns 110,249 shares of the biotechnology company’s stock worth $442,000 after buying an additional 106,116 shares in the last quarter.
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pfenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.